Strategic Acquisition SIGMA became part of the ZETA Group in 2022 and was fully acquired by ZETA Biopharma in October 2025, signaling a strong backing from a global pharmaceutical and biotech-focused EPCM contractor. Sales opportunity: leverage ZETA’s extended pharma/biotech footprint to cross-sell integrated automation and manufacturing intelligence solutions.

Industry Focus Core customers span pharma, biotechnology, vaccine development, diagnostics, chemistry, food & beverage, and water treatment. Sales potential lies in expanding automation, process optimization, and compliance-enabled solutions tailored to highly regulated sectors with stringent quality and traceability needs.

Tech Stack Utilizes Microsoft Power Automate, Power BI, Tableau, SharePoint, SQL, Microsoft 365, JavaScript, and VMware, indicating readiness for data-driven automation, dashboards, and cloud-enabled workflows. Opportunity to upsell advanced analytics, digital twins, and IoT/ Manufacturing Intelligence capabilities.

Growth & Investment Revenue range suggests SME to lower mid-market scale with growth ambitions. Collaborative potential with ZETA could unlock larger projects, accelerated deployment timelines, and access to broader supply chains—ideal for multi-site pharma/biotech implementations.

Recent News Signal Acquisition by ZETA Biopharma implies strategic alignment and potential for bundled solutions, extended service agreements, and long-term maintenance contracts. Prospect for managed services, lifecycle support, and integration services across the ZETA-enabled ecosystem.